U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07465432) titled 'Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries' on Feb. 11.
Brief Summary: Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval n...